Veterinary Medicines

Zipyran Plus 50 mg + 145 mg + 150 mg Tabletka

Authorised
  • Praziquantel
  • Pyrantel embonate
  • Febantel
Download as PDF

Product identification

Medicine name:
Zipyran Plus 50 mg + 145 mg + 150 mg Tabletka
Active substance:
  • Praziquantel
  • Pyrantel embonate
  • Febantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    145.00
    milligram(s)
    /
    1.00
    Tablet
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Calier S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Calier S.A.
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1363
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 27/12/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 27/12/2024
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 27/12/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."